D-MT prompts the anti-tumor effect of oxaliplatin by inhibiting IDO expression in a mouse model of colon cancer

Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy

(2021) Yixuan Guo et al.   BIOMATERIALS

Tumor Microenvironment

(2020) Borros Arneth   Medicina-Lithuania

Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy

(2020) Mara De Martino et al.   OncoImmunology

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies

(2020) Lijie Zhai et al.   Frontiers in Immunology

Tumor-Targeted Gene Silencing IDO Synergizes PTT-Induced Apoptosis and Enhances Anti-tumor Immunity

(2020) Yujuan Zhang et al.   Frontiers in Immunology

Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells

(2020) Azubuike Peter Ebokaiwe et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

MiR-669b-3p regulates CD4+ T cell function by down-regulating indoleamine-2, 3-dioxygenase

(2020) Chuan Li et al.   TRANSPLANT IMMUNOLOGY

IDO Expression in Cancer: Different Compartment, Different Functionality?

(2020) Annabel Meireson et al.   Frontiers in Immunology

AKT2 phosphorylation of hexokinase 2 at T473 promotes tumorigenesis and metastasis in colon cancer cells via NF-κB, HIF1α, MMP2, and MMP9 upregulation

(2019) Hang Li et al.   CELLULAR SIGNALLING

CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin

(2019) Jeanne Galaine et al.   INTERNATIONAL JOURNAL OF CANCER

Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway

(2019) Dechun Liu et al.   NANO LETTERS

STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis

(2019) Christina Heichler et al.   GUT

Prolonged skin grafts survival time by IFN-γ in allogeneic skin transplantation model during acute rejection through IFN-γ/STAT3/IDO pathway in epidermal layer

(2018) Yijie Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer

(2018) Qian Ye et al.   HUMAN PATHOLOGY

Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon

(2018) Vanesa Stojanovska et al.   PLoS One

MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy

(2018) Wei-Wei Ren et al.   Cell Death & Disease

Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma

(2018) Xin Wang et al.   Journal of Cancer

The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy

(2018) Lilla Hornyák et al.   Frontiers in Immunology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Elevated IL-33 promotes expression of MMP2 and MMP9 via activating STAT3 in alveolar macrophages during LPS-induced acute lung injury

(2018) Yafeng Liang et al.   CELLULAR & MOLECULAR BIOLOGY LETTERS

Detection of RAGE expression and its application to diabetic wound age estimation

(2017) Xin-Yi Ji et al.   INTERNATIONAL JOURNAL OF LEGAL MEDICINE

ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway

(2017) Xin Yin et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Effect of Indoleamine 2,3-Dioxygenase Expressed in HTR-8/SVneo Cells on Decidual NK Cell Cytotoxicity

(2016) Yanli Ban et al.   AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY

Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies

(2016) A. M. Monjazeb et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

(2016) Senthamil R. Selvan et al.   CURRENT CANCER DRUG TARGETS

Mechanisms of drug resistance in colon cancer and its therapeutic strategies

(2016) Tao Hu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

(2016) Chunbai He et al.   Nature Communications

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance

(2015) E. Martinez-Balibrea et al.   MOLECULAR CANCER THERAPEUTICS

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia

(2015) Valentina Folgiero et al.   Oncotarget

The role of IDO in brain tumor immunotherapy

(2014) Lijie Zhai et al.   JOURNAL OF NEURO-ONCOLOGY

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials

(2014) Hans-Joachim Schmoll et al.   LANCET ONCOLOGY

The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells

(2013) Ana C. R. Moreno et al.   FEBS Journal

Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas

(2013) Kentaro Mitsuka et al.   NEUROSURGERY

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Influence of Tryptophan Contained in 1-Methyl-Tryptophan on Antimicrobial and Immunoregulatory Functions of Indoleamine 2,3-Dioxygenase

(2012) Silvia K. Schmidt et al.   PLoS One

Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma

(2012) Jin Ye et al.   VIRCHOWS ARCHIV

Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer

(2011) L Ferdinande et al.   BRITISH JOURNAL OF CANCER

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients

(2011) Reinhart Speeckaert et al.   EUROPEAN JOURNAL OF CANCER

Indoleamine 2,3-Dioxygenase+ Cells Correspond to the BDCA2+ Plasmacytoid Dendritic Cells in Human Melanoma Sentinel Nodes

(2009) Gianni Gerlini et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

(2008) M. E.D. Chamuleau et al.   HAEMATOLOGICA